Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial

MLA

Mathilde C.M. Kouwenhoven, et al. “Presence of an Oligodendroglioma-like Component in Newly Diagnosed Glioblastoma Identifies a Pathogenetically Heterogeneous Subgroup and Lacks Prognostic Value: Central Pathology Review of the EORTC_26981/NCIC_CE.3 Trial.” Acta Neuropathologica, vol. 123, Jan. 2012, pp. 841–52. EBSCOhost, https://doi.org/10.1007/s00401-011-0938-4.

APA

Mathilde C.M. Kouwenhoven, Karima Mokhtari, René-Olivier Mirimanoff, Marie-France Hamou, Christian Hartmann, Danielle Martinet, Pieter Wesseling, Roger Stupp, A. von Deimling, M. J. van den Bent, Michael Weller, N Besuchet Schmutz, Wanyu L. Lambiv, Robert-Charles Janzer, Thierry Gorlia, Annie-Claire Diserens, Monika E. Hegi, Pierre Bady, & Warren P. Mason. (2012). Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial. Acta Neuropathologica, 123, 841–852. https://doi.org/10.1007/s00401-011-0938-4

Chicago

Mathilde C.M. Kouwenhoven, Karima Mokhtari, René-Olivier Mirimanoff, Marie-France Hamou, Christian Hartmann, Danielle Martinet, Pieter Wesseling, et al. 2012. “Presence of an Oligodendroglioma-like Component in Newly Diagnosed Glioblastoma Identifies a Pathogenetically Heterogeneous Subgroup and Lacks Prognostic Value: Central Pathology Review of the EORTC_26981/NCIC_CE.3 Trial.” Acta Neuropathologica 123 (January): 841–52. doi:10.1007/s00401-011-0938-4.